Trial Outcomes & Findings for A Novel, Non-pharmacological, Intervention for the Management of ADHD in Adolescents (NCT NCT05835336)
NCT ID: NCT05835336
Last Updated: 2025-03-24
Results Overview
The ADHD-RS is a parent report questionnaire that is used to aid in the diagnosis of ADHD in children ranging from ages 5-17. The questionnaire contains 18 symptom items corresponding to the DSM-V criteria for ADHD. The parent rates each symptom item on a 4-point Likert scale ranging from 0 ('Never or Rarely') to 3 ('Very Often'). The total score goes from 0 up to 54. Higher scores mean more symptoms and higher ADHD impairments.
COMPLETED
NA
32 participants
Baseline, 2-month
2025-03-24
Participant Flow
Thirty-two participants met the inclusion criteria. Three participants failed to complete the personalization process, resulting in 29 participants receiving the intervention.
Participant milestones
| Measure |
Active
VIZO Glasses- personalized
VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli
|
|---|---|
|
Overall Study
STARTED
|
32
|
|
Overall Study
Received Intervention
|
29
|
|
Overall Study
COMPLETED
|
24
|
|
Overall Study
NOT COMPLETED
|
8
|
Reasons for withdrawal
| Measure |
Active
VIZO Glasses- personalized
VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli
|
|---|---|
|
Overall Study
Withdrawal by Subject
|
5
|
|
Overall Study
Did not complete the personalization process
|
3
|
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
Active
n=23 Participants
VIZO Glasses- personalized
VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli
|
|---|---|
|
Age, Continuous
|
14.67 years
STANDARD_DEVIATION 1.87 • n=23 Participants
|
|
Sex: Female, Male
Female
|
9 Participants
n=23 Participants
|
|
Sex: Female, Male
Male
|
14 Participants
n=23 Participants
|
|
ADHD Rating Scale (ADHD-RS) Parent-report Questionnaire - Total Score
|
30.30 units on a scale
STANDARD_DEVIATION 5.47 • n=23 Participants
|
PRIMARY outcome
Timeframe: Baseline, 2-monthPopulation: Three participants did not complete the questionnaire.
The ADHD-RS is a parent report questionnaire that is used to aid in the diagnosis of ADHD in children ranging from ages 5-17. The questionnaire contains 18 symptom items corresponding to the DSM-V criteria for ADHD. The parent rates each symptom item on a 4-point Likert scale ranging from 0 ('Never or Rarely') to 3 ('Very Often'). The total score goes from 0 up to 54. Higher scores mean more symptoms and higher ADHD impairments.
Outcome measures
| Measure |
Active
n=20 Participants
VIZO Glasses- personalized
VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli
|
|---|---|
|
Change in the ADHD Rating Scale (ADHD-RS) Parent-report Questionnaire - Total Score - at Baseline and 2 Months Follow up
Baseline
|
30.30 score on a scale
Standard Error 1.22
|
|
Change in the ADHD Rating Scale (ADHD-RS) Parent-report Questionnaire - Total Score - at Baseline and 2 Months Follow up
End of study
|
22.85 score on a scale
Standard Error 2.02
|
PRIMARY outcome
Timeframe: Baseline, 2-monthPopulation: Three participants did not complete the questionnaire.
The Inattention subscale of the ADHD-RS contains 9 symptom items, that are designed to measure the child's attention level on tasks or play activities.The items are rated by the parent on a 4-point Likert scale ranging from 0 ('Never or Rarely') to 3 ('Very Often'). The total score goes from 0 up to 27. Higher scores mean more symptoms and higher ADHD impairments.
Outcome measures
| Measure |
Active
n=20 Participants
VIZO Glasses- personalized
VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli
|
|---|---|
|
Change in the ADHD Rating Scale (ADHD-RS) Parent-report Questionnaire - Inattentiveness Subscale - at Baseline and 2 Months Follow up
Baseline
|
18.00 score on a scale
Standard Error 0.93
|
|
Change in the ADHD Rating Scale (ADHD-RS) Parent-report Questionnaire - Inattentiveness Subscale - at Baseline and 2 Months Follow up
End of study
|
14.10 score on a scale
Standard Error 1.16
|
PRIMARY outcome
Timeframe: Baseline, 2-monthPopulation: Three participants did not complete the questionnaire.
The Hyperactivity-Impulsivity subscale of the ADHD-RS contains 9 symptom items, that are designed to measure the child's hyperactivity level and impulsivity level. The items are rated by the parent on a 4-point Likert scale ranging from 0 ('Never or Rarely') to 3 ('Very Often'). The total score goes from 0 up to 27. Higher scores mean more symptoms and higher ADHD impairments.
Outcome measures
| Measure |
Active
n=20 Participants
VIZO Glasses- personalized
VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli
|
|---|---|
|
Change in the ADHD Rating Scale (ADHD-RS) Parent-report Questionnaire - Hyperactivity-Impulsivity Subscale - at Baseline and 2 Months Follow up
Baseline
|
12.30 score on a scale
Standard Error 1.03
|
|
Change in the ADHD Rating Scale (ADHD-RS) Parent-report Questionnaire - Hyperactivity-Impulsivity Subscale - at Baseline and 2 Months Follow up
End of study
|
8.75 score on a scale
Standard Error 1.23
|
PRIMARY outcome
Timeframe: Baseline, 2-monthPopulation: Four participants did not complete the questionnaire.
The Metacognition Index (MI) of the BRIEF reflects a child's ability to self-manage and monitor tasks cognitively. The subscale is composed of the Initiate, Working Memory, Plan/Organize, Organization of Materials, and Monitor scales of the BRIEF. It uses a Likert-type response format ranging from 1 to 3, where 1 is never, 2 is sometimes, and 3 is often. The MI subscale includes 40-items with score ranges between 0 to 120. Higher values represent worse outcome and greater difficulties with executive functions. High scores indicate executive deficit.
Outcome measures
| Measure |
Active
n=19 Participants
VIZO Glasses- personalized
VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli
|
|---|---|
|
Change in Behavior Rating Inventory of Executive Function (BRIEF) - Metacognitive Index - at Baseline and 2 Months Follow up
Baseline
|
107.89 score on a scale
Standard Error 2.11
|
|
Change in Behavior Rating Inventory of Executive Function (BRIEF) - Metacognitive Index - at Baseline and 2 Months Follow up
End of study
|
102.74 score on a scale
Standard Error 2.94
|
SECONDARY outcome
Timeframe: 2-monthPopulation: One participant did not participate in the clinicial interview.
Based on an interview with the participant, the clinician rates the total improvement on a 7 point scale as follows: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment.
Outcome measures
| Measure |
Active
n=22 Participants
VIZO Glasses- personalized
VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli
|
|---|---|
|
Clinical Global Impression-Improvement (CGI-I) - at 2 Months Follow up
CGI-I score of "1", "2" or "3"
|
21 Participants
|
|
Clinical Global Impression-Improvement (CGI-I) - at 2 Months Follow up
CGI-I score of "4" or higher
|
1 Participants
|
SECONDARY outcome
Timeframe: Baseline, 2-monthPopulation: Four participants did not complete the questionnaire.
The BRIEF is a standardized measure that captures views of executive functions or self-regulation in the everyday environment. The BRIEF is composed of 86 items, where each item is rated by the parent, using a 3-point Likert scale ranging from 1 ('Never') to 3 ('Often'). Total score ranges between 86 to 258. The Global Executive Composite (GEC) is an overarching summary score that incorporates all of the BRIEF clinical scales. High scores indicate executive deficit.
Outcome measures
| Measure |
Active
n=19 Participants
VIZO Glasses- personalized
VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli
|
|---|---|
|
Change in Behavior Rating Inventory of Executive Function (BRIEF) - Global Executive Composite - at Baseline and 2 Months Follow up
Baseline
|
161.47 score on a scale
Standard Error 2.97
|
|
Change in Behavior Rating Inventory of Executive Function (BRIEF) - Global Executive Composite - at Baseline and 2 Months Follow up
End of study
|
153.89 score on a scale
Standard Error 4.13
|
SECONDARY outcome
Timeframe: Baseline, 2 monthsPopulation: One participant did not complete the test.
Conners' Continuous Performance Test-3 (CPT-3) is an objective test of attention and impulsivity that has been validated in individuals aged 8 years and older. d-prime (d') is a measure of how well the respondent discriminates nontargets (i.e., the letter X) from targets (i.e., all other letters). This variable is also a signal detection statistic that measures the difference between the signal (targets) and noise (non-targets) distributions. In general, the greater the difference between the signal and noise distributions, the better the ability to distinguish non-targets and targets. CPT scores are age and gender standardized T-scores, in which the mean is equal to 50 and the standard deviation is equal to 10. d' is reverse-scored so that higher raw score and T-score values indicate worse performance (i.e., poorer discrimination). Atypical scores are higher than 60 indicating "elevated" to "very elevated" performance.
Outcome measures
| Measure |
Active
n=22 Participants
VIZO Glasses- personalized
VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli
|
|---|---|
|
Change in Conners' Continuous Performance Test-3 (CPT-3) - Detectability (d') at Baseline and 2 Months Follow up
Baseline
|
50.55 T-score
Standard Error 1.64
|
|
Change in Conners' Continuous Performance Test-3 (CPT-3) - Detectability (d') at Baseline and 2 Months Follow up
End of study
|
51.68 T-score
Standard Error 1.70
|
Adverse Events
Active
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Active
n=24 participants at risk
VIZO Glasses- personalized
VIZO Glasses: Eyeglasses with personalized peripheral retinal stimuli
|
|---|---|
|
General disorders
Headache
|
41.7%
10/24 • Adverse event data was collected during the two-month intervention period.
No serious adverse events were reported, and no events led to intervention discontinuation. All side effects were transient, reported to be mild or moderate, and resolved after the removal of the glasses.
|
|
General disorders
Eyestrain
|
16.7%
4/24 • Adverse event data was collected during the two-month intervention period.
No serious adverse events were reported, and no events led to intervention discontinuation. All side effects were transient, reported to be mild or moderate, and resolved after the removal of the glasses.
|
|
General disorders
Discomfort
|
4.2%
1/24 • Adverse event data was collected during the two-month intervention period.
No serious adverse events were reported, and no events led to intervention discontinuation. All side effects were transient, reported to be mild or moderate, and resolved after the removal of the glasses.
|
|
General disorders
Dizziness
|
8.3%
2/24 • Adverse event data was collected during the two-month intervention period.
No serious adverse events were reported, and no events led to intervention discontinuation. All side effects were transient, reported to be mild or moderate, and resolved after the removal of the glasses.
|
|
General disorders
Tiredness
|
8.3%
2/24 • Adverse event data was collected during the two-month intervention period.
No serious adverse events were reported, and no events led to intervention discontinuation. All side effects were transient, reported to be mild or moderate, and resolved after the removal of the glasses.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place